MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

The Global Parkinson’s Genetics Program: Expanding the Diversity of Neurological Disorder Data: 2025 Update

GP2. Parkinson'S_genetics_program (Chevy Chase, USA)

Meeting: 2025 International Congress

Keywords: Dementia with Lewy bodies (DLB), Parkinson’s, Progressive supranuclear palsy(PSP)

Category: Parkinson's Disease: Genetics

Objective: To broaden the available data for Parkinson’s Disease (PD) and related disorders by integrating genetic data from more than 115,000 participants worldwide through genotyping and whole genome sequencing, complemented by enhanced quality control procedures and the inclusion of geographically-restricted GDPR-compliant samples.

Background: The latest data release from the Global Parkinson’s Genetics Program (GP2) significantly expands the genetic information accessible, providing extensive genetic and clinical datasets across 11 ancestry classifications to more accurately represent global genetic diversity.

Method: Quality control protocols with GenoTools (v1.0.0) ensure data integrity, and variant calling in the whole genome sequences uses DeepVariant-GLnexus for accuracy. Using our ancestry prediction machine learning model, based on the 1000 Genomes (1KG) panel among other reference datasets, we classify participants into one of 11 ancestry groups.

Results: The incorporation of GDPR-compliant samples from local sources through the Verily Viewpoint Workbench, along with extensive clinical data for approximately 20,000 individuals, represents a substantial advancement. The updated dataset contains about 42,000 PD cases, 24,000 controls, and 28,000 individuals with other phenotypes who have been genotyped. Additionally, it includes whole genome sequences for roughly 34,000 individuals. Furthermore, we have made 10,454 clinical exomes available.

Conclusion: The consistent updates from GP2 continue to enrich the research landscape by emphasizing diversity, improving quality controls, and integrating detailed clinical data. These enhancements are poised to propel forward our understanding and treatment of PD and related dementias. Beyond just data, GP2 has fostered a collaborative network equipped with training materials, support for project proposals and management, and analysis assistance. This comprehensive approach ensures that researchers are well-supported to leverage these resources effectively.

To cite this abstract in AMA style:

GP2. Parkinson'S_genetics_program. The Global Parkinson’s Genetics Program: Expanding the Diversity of Neurological Disorder Data: 2025 Update [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/the-global-parkinsons-genetics-program-expanding-the-diversity-of-neurological-disorder-data-2025-update/. Accessed October 5, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-global-parkinsons-genetics-program-expanding-the-diversity-of-neurological-disorder-data-2025-update/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley